​

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALNY Stock Forecast

Alnylam Pharmaceuticals (ALNY) stock forecast, based on 43 Wall Street analysts, predicts a 12-month average price target of $328.00, with a high of $338.00 and a low of $310.00. This represents a 42.30% increase from the last price of $230.50.

$100 $150 $200 $250 $300 $350 High: $338 Avg: $328 Low: $310 Last Closed Price: $230.5

ALNY Stock Rating

Alnylam Pharmaceuticals stock's rating consensus is Buy, based on 43 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 35 Buy (81.40%), 7 Hold (16.28%), 1 Sell (2.33%), and 0 Strong Sell (0.00%).

Buy
Total 43 1 7 35 Strong Sell Sell Hold Buy Strong Buy

ALNY Price Target Upside V Benchmarks

TypeNameUpside
StockAlnylam Pharmaceuticals42.30%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts1118
Avg Price Target$338.00$338.00$304.11
Last Closing Price$230.50$230.50$230.50
Upside/Downside46.64%46.64%31.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25121281-33
Mar, 25111191-32
Feb, 25111181132
Jan, 25111181132
Dec, 24111181132
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 21, 2025Scotiabank$338.00$283.3419.29%46.64%
Jan 07, 2025William PickeringBernstein$310.00$235.9531.38%34.49%
Oct 24, 2024Whitney IjemCanaccord Genuity$336.00$294.8713.95%45.77%
Oct 01, 2024Whitney IjemCanaccord Genuity$366.00$273.6933.73%58.79%
Sep 27, 2024Tazeen AhmadBank of America Securities$307.00$274.9111.67%33.19%
Aug 27, 2024Kostas BiliourisBMO Capital$300.00$269.3111.40%30.15%
Aug 26, 2024Luca IssiRBC Capital$300.00$271.4310.53%30.15%
Aug 16, 2024Salveen RichterGoldman Sachs$370.00$262.7040.85%60.52%
Jul 08, 2024Whitney IjemCanaccord Genuity$357.00$253.8640.63%54.88%
Jun 28, 2024Esther RajaveluUBS$288.00$247.0016.60%24.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 21, 2025ScotiabankOutperformOutperformhold
Jan 07, 2025BernsteinOutperformOutperformhold
Oct 24, 2024Canaccord GenuityBuyBuyhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 18, 2024H.C. WainwrightBuyBuyhold
Oct 01, 2024Canaccord GenuityBuyBuyhold
Sep 27, 2024Bank of America SecuritiesBuyBuyhold
Sep 03, 2024OppenheimerPerformPerformhold
Sep 03, 2024Wolfe ResearchNegativeNegativehold
Sep 03, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.46$-7.20$-9.30$-3.52-----
Avg Forecast$-7.20$-6.44$-8.95$-3.48$-2.10$-1.04$2.91$6.52$12.25
High Forecast$-6.05$-5.41$-7.68$-2.38$0.75$4.40$9.93$19.04$15.89
Low Forecast$-8.50$-7.61$-10.93$-4.20$-3.77$-11.85$-1.93$2.05$10.34
Surprise %3.61%11.80%3.91%1.15%-----

Revenue Forecast

$0 $2B $3B $5B $6B $8B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$492.85M$844.29M$1.04B$1.83B$2.25B----
Avg Forecast$475.26M$820.81M$1.01B$1.83B$2.24B$2.65B$3.54B$4.54B$5.85B
High Forecast$541.27M$934.80M$1.19B$1.88B$2.27B$3.06B$3.55B$4.61B$7.19B
Low Forecast$416.86M$719.95M$902.76M$1.77B$2.20B$2.40B$3.53B$4.47B$5.15B
Surprise %3.70%2.86%2.38%0.12%0.35%----

Net Income Forecast

$-2B $-700M $100M $900M $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-858.28M$-852.82M$-1.13B$-440.24M$-278.16M----
Avg Forecast$-777.85M$-723.17M$-770.44M$-440.24M$-332.26M$-196.87M$330.06M$942.06M$1.53B
High Forecast$-622.28M$-578.53M$-616.35M$-352.19M$94.21M$549.62M$1.24B$2.38B$1.99B
Low Forecast$-933.41M$-867.80M$-924.53M$-528.29M$-471.06M$-1.48B$-240.59M$255.91M$1.29B
Surprise %10.34%17.93%46.82%--16.28%----

ALNY Forecast FAQ

Is Alnylam Pharmaceuticals stock a buy?

Alnylam Pharmaceuticals stock has a consensus rating of Buy, based on 43 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 35 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Alnylam Pharmaceuticals is a favorable investment for most analysts.

What is Alnylam Pharmaceuticals's price target?

Alnylam Pharmaceuticals's price target, set by 43 Wall Street analysts, averages $328 over the next 12 months. The price target range spans from $310 at the low end to $338 at the high end, suggesting a potential 42.30% change from the previous closing price of $230.5.

How does Alnylam Pharmaceuticals stock forecast compare to its benchmarks?

Alnylam Pharmaceuticals's stock forecast shows a 42.30% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Alnylam Pharmaceuticals over the past three months?

  • April 2025: 36.36% Strong Buy, 36.36% Buy, 24.24% Hold, 3.03% Sell, 0% Strong Sell.
  • March 2025: 34.38% Strong Buy, 34.38% Buy, 28.12% Hold, 3.12% Sell, 0% Strong Sell.
  • February 2025: 34.38% Strong Buy, 34.38% Buy, 25.00% Hold, 3.12% Sell, 3.12% Strong Sell.

What is Alnylam Pharmaceuticals’s EPS forecast?

Alnylam Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.04, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $2.91 in 2026, $6.52 in 2027, and $12.25 in 2028.

What is Alnylam Pharmaceuticals’s revenue forecast?

Alnylam Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $2.65B, reflecting a 17.76% increase from the reported $2.25B in 2024. The forecast for 2026 is $3.54B, followed by $4.54B for 2027, and $5.85B for 2028.

What is Alnylam Pharmaceuticals’s net income forecast?

Alnylam Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-197M, representing a -29.22% decrease from the reported $-278M in 2024. Projections indicate $330.06M in 2026, $942.06M in 2027, and $1.53B in 2028.